Latanoprostene Bunod 0.024% in Patients with Open-Angle Glaucoma Switched from Prior Pharmacotherapy: A Retrospective Chart Review.

Introduction: Latanoprostene bunod 0.024% (LBN, Vyzulta) is a nitric oxide-donating prostaglandin analog (PGA). We investigated the real-world efficacy and safety of LBN in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) who switched their existing intraocular pressure (IOP)-lowering treatment(s) to LBN.

Retrospective Chart Review on Real-World Use of Latanoprostene Bunod 0.024% in Treatment-Naïve Patients with Open-Angle Glaucoma.

Introduction: The objective of this study was to evaluate real-world effectiveness of latanoprostene bunod (LBN) ophthalmic solution 0.024% in treatment-naïve patients newly diagnosed with open-angle glaucoma (OAG) or ocular hypertension.

Methods: This multicenter retrospective chart review included patients aged ≥ 18 years, with no history of medical, laser, or surgical intraocular pressure (IOP)-lowering intervention and at least two follow-up visits (spanning ≥ 2 months) following initiation of LBN treatment.

Trabectome success factors.

Our objective is to investigate which factors and patient characteristics are associated with success in Trabectome surgery.A total of 658 phakic cases with at least of 12 months follow-up were included in the analysis. Baseline demographics and medical data were collected.

Interventions improve poor adherence with once daily glaucoma medications in electronically monitored patients.

Purpose: To investigate the impact of an intervention program to improve adherence with topical, once daily therapy for glaucoma.

Design: Randomized controlled clinical trial.

Participants: Sixty-six patients with glaucoma being treated with a prostaglandin analog in 1 or both eyes at the Scheie Eye Institute or Wilmer Eye Institute between November 2006 and June 2007.

Risk factors for poor adherence to eyedrops in electronically monitored patients with glaucoma.

Purpose: To identify risk factors for poor adherence to topical once daily therapy for glaucoma.

Design: Prospective, observational cohort study.

Participants: A total of 196 patients with glaucoma who were being treated with a prostaglandin analog in 1 or more eyes at the Scheie or Wilmer Eye Institutes between August 2006 and June 2007.

Adherence with topical glaucoma medication monitored electronically the Travatan Dosing Aid study.

Purpose: To assess patient adherence and behaviors with topical once-daily therapy for glaucoma.

Design: Prospective, observational cohort study.

Participants: One hundred ninety-six patients with glaucoma who were being treated with a prostaglandin analog in 1 or both eyes at the Scheie or Wilmer Eye Institutes between August 2006 and June 2007.